+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Small Molecules Drugs for Inflammatory Bowel Diseases Market by Indication, Mechanism of Action, Distribution Channel, Treatment Type, Therapy Line, Development Stage - Global Forecast 2025-2030- Product Image
Small Molecules Drugs for Inflammatory Bowel Diseases Market by Indication, Mechanism of Action, Distribution Channel, Treatment Type, Therapy Line, Development Stage - Global Forecast 2025-2030- Product Image
Sale

Small Molecules Drugs for Inflammatory Bowel Diseases Market by Indication, Mechanism of Action, Distribution Channel, Treatment Type, Therapy Line, Development Stage - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083023
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Inflammatory bowel disease (IBD), driven by unmet clinical needs and evolving patient profiles, is experiencing a strategic shift in therapeutic approaches, especially as small molecule drugs redefine standards in Crohn disease and ulcerative colitis care. Senior decision-makers are now focusing on the transformative potential of oral, targeted therapies that streamline disease management and respond to emerging regulatory and economic pressures.

Market Snapshot: IBD Small Molecule Therapeutics

The global IBD market is entering a phase of renewed innovation and expanding opportunity, propelled by increasing prevalence across diverse populations and a gradual transition from biologic- to small molecule-based regimens. Therapies such as JAK inhibitors, PDE4 inhibitors, and S1P receptor modulators offer oral administration and differentiated safety profiles, responding to a growing demand for treatments that address quality of life, minimize logistical barriers, and enable scalable adoption across outpatient settings. The market landscape continues to shift as late-stage pipelines mature, regulatory agility accelerates approvals, and both established players and biotech innovators vie for positioning.

Scope & Segmentation

This report delivers deep segmentation and strategic insights relevant for stakeholders seeking to navigate the evolving small molecule landscape in IBD. Coverage includes:

  • Indications: • Crohn Disease (mild, moderate, severe) • Ulcerative Colitis (mild, moderate, severe)
  • Mechanism of Action: • JAK Inhibitors (JAK1 selective, pan-JAK variants) • PDE4 Inhibitors • S1P Receptor Modulators (S1P1-focused, S1P1/5 dual agents)
  • Distribution Channel: • Hospital Pharmacy • Online Pharmacy • Retail Pharmacy
  • Treatment Type: • Induction Therapy • Maintenance Therapy
  • Therapy Line: • First Line • Second Line • Third Line and Beyond
  • Development Stage: • Approved • Clinical Phase II • Clinical Phase III
  • Regions: • Americas (including United States and sub-national detail, Canada, Mexico, Brazil, Argentina) • Europe, Middle East & Africa (country-level coverage extends from major EU markets to emerging regional economies) • Asia-Pacific (with focus on China, India, Japan, and other key growth territories)
  • Company Profiles: • Pfizer Inc. • AbbVie Inc. • Bristol-Myers Squibb Company • Gilead Sciences, Inc. • Arena Pharmaceuticals, Inc. • Galapagos NV

Key Takeaways

  • Market momentum is driven by patient demand for oral, convenient therapies with rapid induction and sustainable remission, emphasizing real-world outcomes over traditional endpoints.
  • Regulatory agencies are enabling faster commercialization pathways for small molecule agents with adaptive approval models, especially those demonstrating clear benefit in both induction and maintenance phases.
  • Segmentation by disease severity and mechanism of action supports targeted product development and precise therapy positioning, crucial for competitive advantage in a crowded market.
  • Strategic partnerships—spanning clinical trial collaborations to digital health integrations—enhance product differentiation and support long-term patient engagement, bolstering adoption and real-world evidence generation.
  • Emerging regional variations in access, payer expectations, and distribution channel maturity require tailored market-entry strategies to maximize product uptake and align with regulatory requirements.

Tariff Impact: Implications for Small Molecule IBD Therapies

U.S. tariff policy changes in 2025 are expected to impact sourcing costs and pricing structures for small molecule therapies, necessitating robust procurement strategies. Industry will need to address potential short-term disruptions through localized production, diversified supplier networks, and value-based contracting with payers to protect both affordability and supply chain resilience.

Methodology & Data Sources

This analysis applies a rigorous, multi-source methodology featuring comprehensive secondary literature review, in-depth interviews with clinical and industry experts, and triangulation of quantitative trial data with qualitative stakeholder insight. An iterative validation protocol strengthens reliability, ensuring findings reflect consensus across the IBD small molecule therapeutics sector.

Why This Report Matters

  • Enables senior stakeholders to benchmark strategic decisions against evolving segmentation, market dynamics, and regulatory developments unique to small molecule IBD therapies.
  • Delivers actionable intelligence on how regional, channel, and clinical factors converge to shape adoption, investment, and commercialization priorities.
  • Empowers organizations to pre-empt tariff-driven changes and optimize their competitive position in both mature and growth markets.

Conclusion

The IBD small molecule therapeutics market is shaped by accelerating innovation, evolving patient needs, and dynamic tariff and regulatory environments. Strategic alignment across development, market access, and digital engagement remains essential for capturing growth and leadership in this changing sector.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing clinical adoption of highly selective JAK1 inhibitors for ulcerative colitis
5.2. Emergence of gut-selective sphingosine 1-phosphate modulators aimed at Crohn’s disease patients
5.3. Advancements in oral small molecule integrin antagonists targeting gut mucosal trafficking
5.4. Growing interest in PDE4 inhibitors with improved safety profiles for mild to moderate IBD
5.5. Integration of pharmacogenomic biomarkers to optimize small molecule therapy personalization
5.6. Expansion of real-world evidence studies evaluating long-term small molecule safety in IBD
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Indication
8.1. Introduction
8.2. Crohn Disease
8.2.1. Mild
8.2.2. Moderate
8.2.3. Severe
8.3. Ulcerative Colitis
8.3.1. Mild
8.3.2. Moderate
8.3.3. Severe
9. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Mechanism Of Action
9.1. Introduction
9.2. JAK Inhibitors
9.2.1. JAK1 Selective Inhibitors
9.2.2. Pan JAK Inhibitors
9.3. PDE4 Inhibitors
9.4. S1P Receptor Modulators
9.4.1. S1P1 Modulators
9.4.2. S1P1/5 Modulators
10. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Treatment Type
11.1. Introduction
11.2. Induction Therapy
11.3. Maintenance Therapy
12. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Therapy Line
12.1. Introduction
12.2. First Line
12.3. Second Line
12.4. Third Line And Beyond
13. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Development Stage
13.1. Introduction
13.2. Approved
13.3. Clinical Phase II
13.4. Clinical Phase III
14. Americas Small Molecules Drugs for Inflammatory Bowel Diseases Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Small Molecules Drugs for Inflammatory Bowel Diseases Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Small Molecules Drugs for Inflammatory Bowel Diseases Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. AbbVie Inc.
17.3.3. Bristol-Myers Squibb Company
17.3.4. Gilead Sciences, Inc.
17.3.5. Arena Pharmaceuticals, Inc.
17.3.6. Galapagos NV
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET: RESEARCHAI
FIGURE 28. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET: RESEARCHSTATISTICS
FIGURE 29. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET: RESEARCHCONTACTS
FIGURE 30. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK1 SELECTIVE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK1 SELECTIVE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PAN JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PAN JAK INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1 MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1 MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1/5 MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1/5 MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDUCTION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDUCTION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY APPROVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY APPROVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE II, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE II, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE III, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE III, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 125. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 126. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 127. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 128. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 129. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 130. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 131. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 132. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 133. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 134. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 135. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 136. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 137. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 140. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 141. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 142. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 143. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 144. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 145. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 146. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 147. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 148. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 149. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 150. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 151. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 152. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 153. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 154. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 155. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 156. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 157. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 160. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 161. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 162. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 163. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 164. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM SMALL MOLECULES DRUGS FO

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Small Molecules Drugs for Inflammatory Bowel Diseases market report include:
  • Pfizer Inc.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Arena Pharmaceuticals, Inc.
  • Galapagos NV

Related Topics

Related Reports

Inflammatory Bowel Disease (IBD) Therapeutics - Global Strategic Business Report - Product Image

Inflammatory Bowel Disease (IBD) Therapeutics - Global Strategic Business Report

  • Report
  • 146 Pages
  • Global
From
Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market - Product Image

Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market

  • Report
  • 155 Pages
  • Global
From
Inflammatory Bowel Disease Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Inflammatory Bowel Disease Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 170 Pages
  • Global
From
Inflammatory Bowel Disease Treatment Market - A Global and Regional Analysis: Focus on Route of Administration, Drug Class, Distribution Channel, Type, and Country-Level Analysis - Analysis and Forecast, 2025-2035 - Product Image

Inflammatory Bowel Disease Treatment Market - A Global and Regional Analysis: Focus on Route of Administration, Drug Class, Distribution Channel, Type, and Country-Level Analysis - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Small Molecule aIIbß3 Antagonists Market by Indication (Acute Coronary Syndrome, Percutaneous Coronary Intervention), Product (Eptifibatide, Lamifiban, Lotrafiban), Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Small Molecule aIIbß3 Antagonists Market by Indication (Acute Coronary Syndrome, Percutaneous Coronary Intervention), Product (Eptifibatide, Lamifiban, Lotrafiban), Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.